eFFECTOR Therapeutics, Inc. (EFTR)

2.2000 +0.0400 (+1.85%) At close: 04:00PM EDT

eFFECTOR Therapeutics, Inc.

142 North Cedros Avenue
Suite B
Solana Beach, CA 92075
United States
858 925 8215
https://effector.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 14

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Stephen T. Worland Ph.D.	CEO, President & Director	873.96k	N/A	1958
Mr. Michael Byrnes M.B.A.	Chief Financial Officer	654.82k	N/A	1977
Dr. Douglas Warner M.D.	Chief Medical Officer	660.16k	N/A	1972
Dr. Davide Ruggero Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A
Dr. Kevan M. Shokat Ph.D.	Co-Founder and Member of Clinical & Scientific Advisory Board	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.

Corporate Governance

eFFECTOR Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.